Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLong-Term Debt IssuancesReceivables - Net
Ratios

Regen BioPharma (RGBPP) Short-Term Debt repayments (2016 - 2023)

Regen BioPharma (RGBPP) has disclosed Short-Term Debt repayments for 9 consecutive years, with $100000.0 as the latest value for Q1 2023.

  • On a quarterly basis, Short-Term Debt repayments changed N/A to $100000.0 in Q1 2023 year-over-year; TTM through Jun 2023 was $100000.0, a N/A change, with the full-year FY2022 number at $499.0, down 99.96% from a year prior.
  • Short-Term Debt repayments was $100000.0 for Q1 2023 at Regen BioPharma, down from $1.4 million in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $1.4 million in Q3 2021 to a low of -$47900.0 in Q2 2021.
  • A 4-year average of $190625.0 and a median of $17193.5 in 2019 define the central range for Short-Term Debt repayments.
  • Peak YoY movement for Short-Term Debt repayments: soared 962.9% in 2019, then tumbled 37.65% in 2020.
  • Regen BioPharma's Short-Term Debt repayments stood at -$31800.0 in 2019, then soared by 116.67% to $5300.0 in 2020, then skyrocketed by 26522.64% to $1.4 million in 2021, then plummeted by 92.91% to $100000.0 in 2023.
  • Per Business Quant, the three most recent readings for RGBPP's Short-Term Debt repayments are $100000.0 (Q1 2023), $1.4 million (Q3 2021), and -$47900.0 (Q2 2021).